

ELEVATE

Formulary Updates to Elevate Plans
(Bronze HDHP/Standard,
Silver Select/Standard,
Gold Select/Standard)

P&T/Formulary Committee Actions
1Q2021 (Effective April 1, 2021)

1Q21 Formulary Actions

1Q21 Formulary Actions																
Drug							Formulary Status		Utilization Management							
							Marketplace (HIE)		Marketplace (HIE)							
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	Rationale of Changes	Optional Benefit Exclusion	Optional Non-Essential Exclusion (PFI/HIE)	FORMULARY CHANGE EFFECTIVE 4/1/2021	FORMULARY CHANGE EFFECTIVE 10/1/2021	Client Communication - HIE
ASTHMA AND COPD	SYMBICORT	BUDESONIDE/FORMOTEROL FUMARATE	160-4.5MCG	HFA AER AD	INHALATION	MSB/ GENERIC	2	S=2	QL	C=QL	Clinical/Safety Strategy			ALL CHANGES		QL: LIMITED TO 30.6 GM PER 30 DAYS
ASTHMA AND COPD	SYMBICORT	BUDESONIDE/FORMOTEROL FUMARATE	80-4.5 MCG	HFA AER AD	INHALATION	MSB/ GENERIC	2	S=2	QL	C=QL	Clinical/Safety Strategy				ALL CHANGES	QL: LIMITED TO 30.6 GM PER 30 DAYS
ASTHMA AND COPD	DULERA	MOMETASONE/FORMOTEROL	100-5 MCG	HFA AER AD	INHALATION	SSB	3	S=3	QL	S=ST C=QL	Clinical/Safety Strategy			ALL CHANGES		QL: LIMITED TO 39 GM PER 30 DAYS
ASTHMA AND COPD	DULERA	MOMETASONE/FORMOTEROL	50MCG-5MCG	HFA AER AD	INHALATION	SSB	3	S=3	QL	S=ST C=QL	Clinical/Safety Strategy				ALL CHANGES	QL: LIMITED TO 39 GM PER 30 DAYS
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	150 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		ALL CHANGES		
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	150 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		ALL CHANGES		
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	75MG/0.5ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		ALL CHANGES		
BEHAVIORAL HEALTH - OTHER	HETLIOZ	TASIMELTEON	20 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			ALL CHANGES		
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIOCIGUAT	0.5 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIOCIGUAT	1 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIOCIGUAT	1.5 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIOCIGUAT	2 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
CARDIOVASCULAR DISEASE - HYPERTENSION	ADEMPAS	RIOCIGUAT	2.5 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
DERMATOLOGY - ANTIINFECTIVE	GENTAMICIN SULFATE	GENTAMICIN SULFATE	0.1 %	OINT. (G)	TOPICAL	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 90 GM PER FILL
DERMATOLOGY - ANTIINFECTIVE	MUPIROCI	MUPIROCI	2 %	OINT. (G)	TOPICAL	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 90 GM PER FILL
DERMATOLOGY - ANTIINFECTIVE	NYSTATIN	NYSTATIN	100000/G	OINT. (G)	TOPICAL	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 90 GM PER FILL
DERMATOLOGY - ANTIINFECTIVE	NYSTATIN-TRIAMCINOLONE	NYSTATIN/TRIAMCINOLONE	100000-0.1	OINT. (G)	TOPICAL	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 180 GM PER FILL
DERMATOLOGY - ANTIINFECTIVE	NYSTATIN-TRIAMCINOLONE	NYSTATIN/TRIAMCINOLONE	100000-0.1	OINT. (G)	TOPICAL	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 180 GM PER FILL
DERMATOLOGY - ANTIINFLAMMATORY	AMCINONIDE	AMCINONIDE	0.1 %	CREAM (G)	TOPICAL	GENERIC	1	S=1	NONE	A=ST	Low Net Cost Strategy			ALL CHANGES		ST: TRIAL OF BETAMETHASONE 0.1% OINT, FLUTICASONE 0.005% OINT, TRIAMCINOLONE 0.5% (OINT, CREAM), OR MOMETASONE 0.1% OINT IN THE PAST 120 DAYS.
DERMATOLOGY - ANTIINFLAMMATORY	AMCINONIDE	AMCINONIDE	0.1 %	LOTION	TOPICAL	GENERIC	1	S=1	NONE	A=ST	Low Net Cost Strategy			ALL CHANGES		ST: TRIAL OF BETAMETHASONE 0.1% OINT, FLUTICASONE 0.005% OINT, TRIAMCINOLONE 0.5% (OINT, CREAM), OR MOMETASONE 0.1% OINT IN THE PAST 120 DAYS.
DERMATOLOGY - ANTIINFLAMMATORY	IMPEKLO	CLOBETASOL PROPIONATE	0.05 %	LOT MD PMP	TOPICAL	SSB	3	S=3	NONE	A=ST	Low Net Cost Strategy			ALL CHANGES		ST: TRIAL OF 1 OF THE FOLLOWING: BETAMETHASONE AUGMENTED (OINT, GEL, LOTION), FLUCINONIDE 0.1% CREAM, CLOBETASOL (SPRAY, LOTION, GEL, OINT, CRM, SOLN), OR HALOBETASOL 0.05% (CREAM, OINT) IN PAST 120 DAYS.
DERMATOLOGY - MISCELLANEOUS	PANRETIN	ALITRETINOIN	0.1 %	GEL (GRAM)	TOPICAL	SSB	4	S=4	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 60 GM PER 28 DAYS.
DERMATOLOGY - PSORIASIS/ECZEMA	ENSTILAR	CALCIPOTRIENE/BETA METHASONE	0.005-.064	FOAM	TOPICAL	SSB	3	S=3	ST	C=ST	Low Net Cost Strategy			ALL CHANGES		ST: TRIAL OF GENERIC TACLONEX OINTMENT IN THE PAST 120 DAYS.
DERMATOLOGY - PSORIASIS/ECZEMA	WYNZORA	CALCIPOTRIENE/BETA METHASONE	0.005-.064	CREAM (G)	TOPICAL	SSB	3	S=3	NONE	A=ST	Low Net Cost Strategy			ALL CHANGES		ST: TRIAL OF GENERIC TACLONEX OINTMENT IN THE PAST 120 DAYS.
EYE - GENERAL DISORDERS	LASTACFT	ALCAFTADINE	0.25 %	DROPS	OPHTHALMIC	SSB	3	S=3	QL	S=ST C=QL	Low Net Cost Strategy			ALL CHANGES		QL: LIMITED TO 6 ML PER 30 DAYS
EYE - GENERAL DISORDERS	AZELASTINE HCL	AZELASTINE HCL	0.05 %	DROPS	OPHTHALMIC	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 12 ML PER 30 DAYS
EYE - GENERAL DISORDERS	CROMOLYN SODIUM	CROMOLYN SODIUM	4 %	DROPS	OPHTHALMIC	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 50 ML PER 30 DAYS
EYE - GENERAL DISORDERS	MAXIDEX	DEXAMETHASONE	0.1 %	DROPS SUSP	OPHTHALMIC	SSB	3	S=3	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	ST: TRIAL OF GENERIC OPHTHALMIC FLUOROMETHOLONE 0.1%, DEXAMETHASONE 0.1%, OR PREDNISOLONE 1% IN THE PAST 120 DAYS.
EYE - GENERAL DISORDERS	DEXAMETHASONE SODIUM PHOSPHATE	DEXAMETHASONE SODIUM PHOSPHATE	0.1 %	DROPS	OPHTHALMIC	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 15 ML PER 14 DAYS
EYE - GENERAL DISORDERS	EPINASTINE HCL	EPINASTINE HCL	0.05 %	DROPS	OPHTHALMIC	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 10 ML PER 30 DAYS
EYE - GENERAL DISORDERS	FLUOROMETHOLONE	FLUOROMETHOLONE	0.1 %	DROPS SUSP	OPHTHALMIC	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				ALL CHANGES	QL: LIMITED TO 10 ML PER 14 DAYS
EYE - GENERAL DISORDERS	FML FORTE	FLUOROMETHOLONE	0.25 %	DROPS SUSP	OPHTHALMIC	SSB	2	S=2	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	QL: LIMITED TO 10 ML PER 14 DAYS
EYE - GENERAL DISORDERS	FML S.O.P.	FLUOROMETHOLONE	0.1 %	OINT. (G)	OPHTHALMIC	SSB	2	S=2	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	ST: TRIAL OF GENERIC OPHTHALMIC FLUOROMETHOLONE 0.1%, DEXAMETHASONE 0.1%, OR PREDNISOLONE 1% IN THE PAST 120 DAYS.

EYE - GENERAL DISORDERS	FLAREX	FLUOROMETHOLONE ACETATE	0.1 %	DROPS SUSP	OPHTHALMIC	SSB	2	S=2	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	QL: LIMITED TO 15 ML PER 14 DAYS ST: TRIAL OF GENERIC OPHTHALMIC FLUOROMETHOLONE 0.1%, DEXAMETHASONE 0.1%, OR PREDNISOLONE 1% IN THE PAST 120 DAYS.
EYE - GENERAL DISORDERS	ALOMIDE	LIDOXAMIDE TROMETHAMINE	0.1 %	DROPS	OPHTHALMIC	SSB	2	S=2	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	QL: LIMITED TO 40 ML PER 30 DAYS ST: TRIAL OF CROMOLYN 4% OPHTHALMIC DROPS IN THE PAST 120 DAYS
EYE - GENERAL DISORDERS	ALREX	LOTEPREDNOL ETABONATE	0.2 %	DROPS SUSP	OPHTHALMIC	SSB	2	S=2	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	QL: LIMITED TO 10 ML PER 14 DAYS ST: TRIAL OF GENERIC OPHTHALMIC ANTIHISTAMINE (EPINASTINE, AZELASTINE, OR OLAPATADINE) IN THE PAST 120 DAYS
EYE - GENERAL DISORDERS	EYSUVIS	LOTEPREDNOL ETABONATE	0.25 %	DROPS SUSP	OPHTHALMIC	SSB	3	S=3	PA	C=PA	Low Net Cost/Trade Relations Strategy			ALL CHANGES		
EYE - GENERAL DISORDERS	ALOCRIL	NEDOCROMIL SODIUM	2 %	DROPS	OPHTHALMIC	SSB	2	S=2	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	QL: LIMITED TO 20 ML PER 30 DAYS ST: TRIAL OF CROMOLYN 4% OPHTHALMIC DROPS IN THE PAST 120 DAYS
EYE - GENERAL DISORDERS	PRED MILD	PREDNISOLONE ACETATE	0.12 %	DROPS SUSP	OPHTHALMIC	SSB	2	S=2	NONE	A=QL A=ST	Low Net Cost Strategy			A=ST	A=QL	QL: LIMITED TO 20 ML PER 14 DAYS ST: TRIAL OF GENERIC OPHTHALMIC FLUOROMETHOLONE 0.1%, DEXAMETHASONE 0.1%, OR PREDNISOLONE 1% IN THE PAST 120 DAYS.
EYE - GENERAL DISORDERS	PREDNISOLONE ACETATE	PREDNISOLONE ACETATE	1 %	DROPS SUSP	OPHTHALMIC	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				All Changes	QL: LIMITED TO 20 ML PER 14 DAYS
EYE - GENERAL DISORDERS	PREDNISOLONE SODIUM PHOSPHATE	PREDNISOLONE SODIUM PHOSPHATE	1 %	DROPS	OPHTHALMIC	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				All Changes	QL: LIMITED TO 20 ML PER 14 DAYS
HEMATOLOGICAL DISORDERS	EPOGEN	EPOETIN ALFA	20000/2ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			ALL CHANGES		
HEMATOLOGICAL DISORDERS	PROCRIT	EPOETIN ALFA	40000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			ALL CHANGES		
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	40000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			ALL CHANGES		
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	1100 MG/11	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		ALL CHANGES		
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	300MG/30ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		ALL CHANGES		
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	300MG/3ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		ALL CHANGES		
INFECTIOUS DISEASE - PARASITIC	ALINIA	NITAZOXANIDE	100 MG/5ML	SUSP RECON	ORAL	SSB	3	S=3	NONE	A=QL	Low Net Cost Strategy				All Changes	QL: LIMITED TO 500 ML PER 10 DAYS
INFECTIOUS DISEASE - PARASITIC	NITAZOXANIDE	NITAZOXANIDE	500 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Low Net Cost Strategy				All Changes	QL: LIMITED TO 20 TABLETS PER 10 DAYS
INFECTIOUS DISEASE - VIRAL	BAMLANIVIMAB (EUA)	BAMLANIVIMAB	700MG/20ML	VIAL	INTRAVEN.	GENERIC	4	S=4	NONE	A=AGE A=QL	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		All Changes		QL: LIMITED TO 20 ML PER FILL AGE: LIMITED TO 12 YEARS AND OLDER
INFECTIOUS DISEASE - VIRAL	CASIRIVIMAB (REGN10933) (EUA)	CASIRIVIMAB (REGN10933)	1332/11.1	VIAL	INTRAVEN.	GENERIC	4	S=4	NONE	A=AGE A=QL	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		All Changes		QL: LIMITED TO 11.1 ML PER FILL AGE: LIMITED TO 12 YEARS AND OLDER
INFECTIOUS DISEASE - VIRAL	CASIRIVIMAB (REGN10933) (EUA)	CASIRIVIMAB (REGN10933)	300 MG/2.5	VIAL	INTRAVEN.	GENERIC	4	S=4	NONE	A=AGE A=QL	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		All Changes		QL: LIMITED TO 10 ML PER FILL AGE: LIMITED TO 12 YEARS AND OLDER
INFECTIOUS DISEASE - VIRAL	ZEPATIER	ELBASVIR/GRAZOPREVIR	50MG-100MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	MAVYRET	GLECAPREVIR/PIBRENTASVIR	100MG-40MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	IMDEVIMAB (REGN10987) (EUA)	IMDEVIMAB (REGN10987)	1332/11.1	VIAL	INTRAVEN.	GENERIC	4	S=4	NONE	A=AGE A=QL	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		All Changes		QL: LIMITED TO 11.1 ML PER FILL AGE: LIMITED TO 12 YEARS AND OLDER
INFECTIOUS DISEASE - VIRAL	IMDEVIMAB (REGN10987) (EUA)	IMDEVIMAB (REGN10987)	300 MG/2.5	VIAL	INTRAVEN.	GENERIC	4	S=4	NONE	A=AGE A=QL	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		All Changes		QL: LIMITED TO 10 ML PER FILL AGE: LIMITED TO 12 YEARS AND OLDER
INFECTIOUS DISEASE - VIRAL	HARVONI	LEDIPASVIR/SOFOSBUVIR	33.75-150	PELET PACK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	HARVONI	LEDIPASVIR/SOFOSBUVIR	45MG-200MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	HARVONI	LEDIPASVIR/SOFOSBUVIR	45MG-200MG	PELET PACK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	HARVONI	LEDIPASVIR/SOFOSBUVIR	90MG-400MG	TABLET	ORAL	SSB/GENERIC	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	VIEKIRA PAK	OMBITA/PARITAP/RIEON/DASABUVIR	12.5-75-50	TAB DS PK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	VIEKIRA XR	OMBITA/PARITAP/RIEON/DASABUVIR	8.33-50 MG	TAB BP 24H	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	REMEDESVIR (EUA)	REMEDESVIR	100MG/20ML	VIAL	INTRAVEN.	GENERIC	4	S=4	NONE	A=QL	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		All Changes		QL: LIMITED TO 220 ML PER 10 DAYS
INFECTIOUS DISEASE - VIRAL	VEKLURY	REMEDESVIR	100 MG	VIAL	INTRAVEN.	SSB	4	S=4	NONE	A=QL	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		All Changes		QL: LIMITED TO 11 VIALS PER 10 DAYS
INFECTIOUS DISEASE - VIRAL	SOVALDI	SOFOSVIR	150 MG	PELET PACK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	SOVALDI	SOFOSVIR	200 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	SOVALDI	SOFOSVIR	200 MG	PELET PACK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	SOVALDI	SOFOSVIR	400 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	EPLUSA	SOFOSVIR/VELPATASVIR	200MG-50MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFECTIOUS DISEASE - VIRAL	EPLUSA	SOFOSVIR/VELPATASVIR	400-100 MG	TABLET	ORAL	SSB/GENERIC	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT	125 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT	50MG/0.4ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT	87.5MG/0.7	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFLAMMATORY DISEASE	ORENCIA CLICKECT	ABATACEPT	125 MG/ML	AUTO INJECT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			ALL CHANGES		
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT/MALTOSE	250 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Non-Self Administered Drug (NSA)		ALL CHANGES		
INFLAMMATORY DISEASE	HUMIRA(CF) PEN	ADALIMUMAB	80MG/0.8ML	PEN IJ KIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			ALL CHANGES		

INFLAMMATORY DISEASE	KINERET	ANAKINRA	100MG/0.67	SYRINGE	SUBCUTANE.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	120 MG	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	200 MG/ML	AUTO INJECT	SUBCUTANE.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	200 MG/ML	SYRINGE	SUBCUTANE.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
INFLAMMATORY DISEASE	BENLYSTA	BELIMUMAB	400 MG	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
INFLAMMATORY DISEASE	ILARIS	CANAKINUMAB/PF	150 MG/ML	VIAL	SUBCUTANE.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
INFLAMMATORY DISEASE	SIMPONI ARIA	GOLIMUMAB	50 MG/4 ML	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Trade Relations Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
INFLAMMATORY DISEASE	ALKINDI SPRINKLE	HYDROCORTISONE	0.5 MG	CAP SPRINK	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
INFLAMMATORY DISEASE	ALKINDI SPRINKLE	HYDROCORTISONE	1 MG	CAP SPRINK	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
INFLAMMATORY DISEASE	ALKINDI SPRINKLE	HYDROCORTISONE	2 MG	CAP SPRINK	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
INFLAMMATORY DISEASE	ALKINDI SPRINKLE	HYDROCORTISONE	5 MG	CAP SPRINK	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
INFLAMMATORY DISEASE	KELIANZ	TOFACITINIB CITRATE	5 MG	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				All Changes	
MISCELLANEOUS AGENTS	PALYNZIQ	PEGVALIASE-PQPZ	20 MG/ML	SYRINGE	SUBCUTANE.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	XTANDI	ENZALUTAMIDE	40 MG	CAPSULE	ORAL	SSB		4	S=4	PA	C=PA	Trade Relations Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	100MG/10ML	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	240MG/24ML	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	40 MG/4 ML	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
NEOPLASTIC DISEASE	TAGRISSO	OSIMERTINIB MESYLATE	40 MG	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	TAGRISSO	OSIMERTINIB MESYLATE	80 MG	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	KEYTRUDA	PEMBROLIZUMAB	100 MG/4ML	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
NEOPLASTIC DISEASE	ICLUSIG	PONATINIB HCL	15 MG	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	ICLUSIG	PONATINIB HCL	45 MG	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	GAVRETO	PRALSETINIB	100 MG	CAPSULE	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	RIABNI	RITUXIMAB-ARRX	10 MG/ML	VIAL	INTRAVEN.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
NEOPLASTIC DISEASE	XPOVIO	SELINEXOR	100MG/WEEK	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	XPOVIO	SELINEXOR	40 MG/WEEK	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	XPOVIO	SELINEXOR	60 MG/WEEK	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
NEOPLASTIC DISEASE	XPOVIO	SELINEXOR	80 MG/WEEK	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
OTHER DRUGS	XEOMIN	INCUBOTULINUMTOXINA	100 UNIT	VIAL	INTRAMUSC.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
OTHER DRUGS	XEOMIN	INCUBOTULINUMTOXINA	200 UNIT	VIAL	INTRAMUSC.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
OTHER DRUGS	XEOMIN	INCUBOTULINUMTOXINA	50 UNIT	VIAL	INTRAMUSC.	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)			ALL CHANGES	
OTHER RESPIRATORY DISORDERS	TRIKAFTA	ELEXACAFTOR/TEZACAFTOR/IVACAFT	100-50-75	TABLET SEQ	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	150 MG	TABLET	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	25 MG	GRAN PACK	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	50 MG	GRAN PACK	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
OTHER RESPIRATORY DISORDERS	KALYDECO	IVACAFTOR	75 MG	GRAN PACK	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
OTHER RESPIRATORY DISORDERS	SYMDEKO	TEZACAFTOR/IVACAFTOR	50 MG-75MG	TABLET SEQ	ORAL	SSB		4	S=4	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
PAIN MANAGEMENT - ANALGESICS	QDOLO	TRAMADOL HCL	5 MG/ML	SOLUTION	ORAL	SSB		3	S=3	PA	C=PA	Clinical/Safety Strategy				ALL CHANGES	
SEIZURE DISORDER	BRIVIACT	BRIVARACETAM	10 MG	TABLET	ORAL	SSB		3	S=3	QL ST	D=ST S=QL	Trade Relations Strategy				All Changes	
SEIZURE DISORDER	BRIVIACT	BRIVARACETAM	10 MG/ML	SOLUTION	ORAL	SSB		3	S=3	QL ST	D=ST S=QL	Trade Relations Strategy				All Changes	
SEIZURE DISORDER	BRIVIACT	BRIVARACETAM	100 MG	TABLET	ORAL	SSB		3	S=3	QL ST	D=ST S=QL	Trade Relations Strategy				All Changes	
SEIZURE DISORDER	BRIVIACT	BRIVARACETAM	25 MG	TABLET	ORAL	SSB		3	S=3	QL ST	D=ST S=QL	Trade Relations Strategy				All Changes	
SEIZURE DISORDER	BRIVIACT	BRIVARACETAM	50 MG	TABLET	ORAL	SSB		3	S=3	QL ST	D=ST S=QL	Trade Relations Strategy				All Changes	
SEIZURE DISORDER	BRIVIACT	BRIVARACETAM	50 MG/5 ML	VIAL	INTRAVEN.	SSB		3	S=3	ST	D=ST	Trade Relations Strategy	Non-Self Administered Drug (NSA)			All Changes	
SEIZURE DISORDER	BRIVIACT	BRIVARACETAM	75 MG	TABLET	ORAL	SSB		3	S=3	QL ST	D=ST S=QL	Trade Relations Strategy				All Changes	
SKELETAL MUSCLE DISORDER	BACLOFEN	BACLOFEN	10 MG	TABLET	ORAL	GENERIC		1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy		ALL CHANGES		QL: LIMITED TO 80 MG PER DAY	
SKELETAL MUSCLE DISORDER	BACLOFEN	BACLOFEN	20 MG	TABLET	ORAL	GENERIC		1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy		ALL CHANGES		QL: LIMITED TO 80 MG PER DAY	
SKELETAL MUSCLE DISORDER	BACLOFEN	BACLOFEN	5 MG	TABLET	ORAL	GENERIC		1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy		ALL CHANGES		QL: LIMITED TO 80 MG PER DAY	

SKELETAL MUSCLE DISORDER	CHLORZOXAZONE	CHLORZOXAZONE	500 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 4 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL	CYCLOBENZAPRINE HCL	10 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 3 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL	CYCLOBENZAPRINE HCL	5 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 3 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL	CYCLOBENZAPRINE HCL	7.5 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 3 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL ER	CYCLOBENZAPRINE HCL	15 MG	CAP ER 24H	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 1 CAPSULE PER DAY
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL ER	CYCLOBENZAPRINE HCL	30 MG	CAP ER 24H	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 1 CAPSULE PER DAY
SKELETAL MUSCLE DISORDER	METAXALONE	METAXALONE	400 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 4 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	METAXALONE	METAXALONE	800 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 4 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	METHOCARBAMOL	METHOCARBAMOL	500 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 8 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	METHOCARBAMOL	METHOCARBAMOL	750 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 6 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	ORPHENADRINE CITRATE ER	ORPHENADRINE CITRATE	100 MG	TABLET ER	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 2 TABLETS PER DAY
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	2 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 36 MG PER DAY
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	2 MG	CAPSULE	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 36 MG PER DAY
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	4 MG	TABLET	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 36 MG PER DAY
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	4 MG	CAPSULE	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 36 MG PER DAY
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	6 MG	CAPSULE	ORAL	GENERIC	1	S=1	NONE	A=QL	Clinical/Safety/Low Net Cost Strategy			ALL CHANGES	QL: LIMITED TO 36 MG PER DAY
OTHER RESPIRATORY DISORDERS	SYMDEKO	TEZACAFTOR/IVACAFTOR	100-150 MG	TABLET SEQ	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy		ALL CHANGES		
WEIGHT REDUCTION	SAXENDA	LIRAGLUTIDE	3 MG/D.S.ML	PEN INJCTR	SUBCUTANE	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy	Antiobesity	ALL CHANGES		
WEIGHT REDUCTION	SETMELANOTIDE ACETATE	SETMELANOTIDE ACETATE	10 MG/ML	VIAL	SUBCUTANE	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Antiobesity	ALL CHANGES		

1Q21 MedImpact Managed Formulary Actions

Additions and/or Revisions effective: 4/1/2021
Deletions effective: 4/1/2021 for NEW member prescriptions
Grandfather until 7/1/2021 for EXISTING member prescriptions

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.

LEGEND

Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co-exist, coverage and copayment for each will be a function of plan benefit design.

FORMULARY		UTILIZATION MANAGEMENT (UM)		OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	S = Sustain	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded		ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		CU = Concurrent Use edit	E = Excluded drug from formulary	Erectile Dysfunction
		PA = Prior Authorization	S = Sustain UM	Infertility
				Medical Foods: Dietary supplements, Enteral Feeding, Infant formula

Non-Self Administered Drug (NSA)
Ostomy Supplies
Class O = Over the Counter Products
Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants